




PHARMACEUTICAL 2023

Regen BioPharma Inc
Rank 402 of 446





PHARMACEUTICAL 2023

Regen BioPharma Inc
Rank 402 of 446

The relative strengths and weaknesses of Regen BioPharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regen BioPharma Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 116% points. The greatest weakness of Regen BioPharma Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 361% points.

The company's Economic Capital Ratio, given in the ranking table, is -249%, being 292% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	336
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,595
Liabilities, Non-Current	0
Other Assets	223
Other Compr. Net Income	0
Other Expenses	389
Other Liabilities	0
Other Net Income	2,893
Other Revenues	126
Property and Equipment	0
Research and Development	158
Selling, General and Administrative Expense	28

Output Variable	Value in 1000 USD
Assets	559
Liabilities	8,595
Expenses	575
Revenues	126
Stockholders Equity	-8,036
Net Income	2,444
Comprehensive Net Income	2,444
Economic Capital Ratio	-249%